SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

28 2 2023 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

27 2 2023 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

09 1 2023 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 1 2023 04:00:01 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

27 12 2022 03:30:07 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

22 11 2022 04:00:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 11 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

29 9 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

10 9 2022 07:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

07 9 2022 06:56:00 提供 Nasdaq GlobeNewswire

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

07 9 2022 06:55:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022

19 8 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 8 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

02 8 2022 04:00:01 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

15 7 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day

10 6 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

09 6 2022 04:00:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

26 5 2022 14:15:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors

24 5 2022 03:30:00 提供 Nasdaq GlobeNewswire

SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022

16 5 2022 05:30:00 提供 Nasdaq GlobeNewswire